Critical Advances in Systemic Therapy for HCC: Building on Recent Progress for Community Practices

Explore recent data surrounding contemporary HCC treatment with this program featuring expert commentaries, an on-demand Webcast, and downloadable slides.
Richard Finn, MD

ClinicalThought

Atezolizumab plus bevacizumab was recently approved as first-line systemic therapy for patients with advanced HCC. Read an expert’s thoughts how this new approach will fit into contemporary treatment paradigms.

Richard Finn, MD Released: September 15, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Eisai
Exelixis, Inc.
Genentech, a member of the Roche Group
Lilly
Merck Sharp & Dohme Corp

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?